Business Wire

AIVEN

29.11.2022 09:02:41 CET | Business Wire | Press release

Share
Aiven boosts leadership team with a slew of new senior appointments

Aiven, the open source cloud data platform company, has announced several key senior leadership appointments who collectively are focused on helping deliver the company’s commitment to democratising access to the best open source technologies while reducing the environmental impact of cloud services.

These strategic new leadership roles span operations and strategy, product marketing, developer relations, and product management and include

  • Katariina Korhonen, Vice President of Strategy and Operations
  • Amy Krishnamohan, Vice President of Product Marketing
  • Ian Massingham, Vice President of Developer Relations and Community
  • Jonah Kowall, Vice President of Product Management

Oskari Saarenmaa, CEO and Co-founder at Aiven, comments on the appointments. “Aiven’s mission is to make developers’ lives better, by helping them build more sophisticated applications accessible to all. When starting Aiven, our goal was to build the company that we wanted to work for. Today we are delighted to be welcoming such a talented group to our leadership team and our wider Aiven community. Our ability to attract the best talent, while also supporting the career growth of our people continues to be instrumental in helping us develop new platform capabilities that bring us closer towards our goal of building more sustainable applications in the cloud.”

Katariina Korhonen has been appointed Vice President of Strategy and Operations to Aiven's Executive Leadership team. Katariina works closely with other senior executives and the board of directors and is focusing on building out Aiven’s corporate, operations, and sustainability strategy globally. Prior to her new role, Katariina spent the last six years in various executive roles at Smartly.

Amy Krishnamohan has also joined as Vice President of Product Marketing with the responsibility for Aiven’s product marketing direction and strategy, and nurturing and engaging with key stakeholders such as analysts, industry thought leaders, and strategic customers to increase the market awareness of Aiven. A Masters alumna of Carnegie Mellon University, Amy has gained diverse experience across product marketing and marketing strategy where she managed open-source database projects and other cloud-native databases. Prior to joining Aiven, she led product marketing strategies from major database companies such as MariaDB and Google Cloud.

Aiven also welcomes Ian Massingham as the company’s Vice President of Developer Relations and Community focusing on further building Aiven’s relationship with the developer community and ensuring that our programs align with our mission of making developers’ lives better. Prior to joining Aiven, Ian led the Developer Relations & Community team at MongoDB. Before that, he played an integral role in establishing and scaling the evangelism and developer relations function at AWS and led Worldwide Solutions Architecture for Startup customers for the final 18 months of his tenure at AWS.

Jonah Kowall has also joined as Aiven’s new Vice President of Product Management. In his role, Jonah will lead and execute the product strategy and head the product team responsible for platform enhancements to support ongoing growth in Aiven’s customer base. Previously a Chief Technology Officer at Logz.io and several other startups, Jonah’s background includes being a Research VP at Gartner and a regular contributor and maintainer of the Open Source Jaeger and OpenTelemetry projects. Jonah joins Aiven and brings with him a wealth of knowledge on all things “observability”.

This latest announcement of senior leadership expansion closely follows the appointment of Olivier van Grembergen as Regional Vice President (RVP) of Aiven Asia Pacific (APAC), announced earlier in October to drive continued growth in the region.

To learn more about Aiven, please visit https://aiven.io/

Free Trial https://console.aiven.io/signup

About Aiven

Headquartered in Helsinki and with hubs in Berlin, Boston, Paris, Singapore, Sydney, Tokyo, and Toronto, Aiven provides managed open source data technologies, like PostgreSQL, Apache Kafka and OpenSearch, on all major clouds. Through Aiven, developers can do what they do best: create applications. Meanwhile, Aiven does what they do best: manage cloud data infrastructure. Aiven enables customers to drive business results from open source that trigger true transformations far beyond their own backyard. Most recently, Aiven achieved a $3B valuation and has now raised $420M total funding backed by its investors Atomico, Earlybird, Eurazeo, IVP, Lifeline, Salesforce Ventures, and World Innovation Lab.

To learn more about Aiven, visit aiven.io and follow @aiven_io on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005090/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye